loading
Schlusskurs vom Vortag:
$11.52
Offen:
$11.66
24-Stunden-Volumen:
1.34M
Relative Volume:
0.62
Marktkapitalisierung:
$1.84B
Einnahmen:
$61.10M
Nettoeinkommen (Verlust:
$-138.36M
KGV:
-8.5556
EPS:
-1.35
Netto-Cashflow:
$-90.59M
1W Leistung:
+4.15%
1M Leistung:
+42.07%
6M Leistung:
+44.56%
1J Leistung:
+46.95%
1-Tages-Spanne:
Value
$11.42
$11.72
1-Wochen-Bereich:
Value
$10.96
$11.72
52-Wochen-Spanne:
Value
$5.80
$11.78

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Name
Firmenname
Ocular Therapeutix Inc
Name
Telefon
781-357-4000
Name
Adresse
15 CROSBY DRIVE, BEDFORD, MA
Name
Mitarbeiter
274
Name
Twitter
@OCUTX
Name
Nächster Verdiensttermin
2025-03-03
Name
Neueste SEC-Einreichungen
Name
OCUL's Discussions on Twitter

Vergleichen Sie OCUL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
OCUL
Ocular Therapeutix Inc
11.55 1.77B 61.10M -138.36M -90.59M -1.35
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-08 Eingeleitet William Blair Outperform
2025-03-18 Eingeleitet RBC Capital Mkts Outperform
2025-03-11 Eingeleitet Needham Buy
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-06-20 Hochstufung TD Cowen Hold → Buy
2024-05-31 Fortgesetzt Piper Sandler Overweight
2024-02-09 Eingeleitet BofA Securities Buy
2023-04-21 Eingeleitet Robert W. Baird Outperform
2022-08-10 Fortgesetzt Berenberg Buy
2021-08-10 Hochstufung H.C. Wainwright Neutral → Buy
2020-12-28 Herabstufung H.C. Wainwright Buy → Neutral
2020-12-17 Eingeleitet Berenberg Buy
2020-11-13 Bestätigt Raymond James Strong Buy
2020-08-10 Bestätigt H.C. Wainwright Buy
2020-03-03 Hochstufung Raymond James Outperform → Strong Buy
2019-05-21 Herabstufung Cowen Outperform → Market Perform
2019-05-21 Bestätigt H.C. Wainwright Buy
2019-05-21 Herabstufung Raymond James Strong Buy → Outperform
2018-12-03 Bestätigt Cantor Fitzgerald Overweight
2018-11-15 Eingeleitet Raymond James Strong Buy
2018-09-07 Eingeleitet Piper Jaffray Overweight
2017-10-24 Eingeleitet Guggenheim Buy
2017-07-26 Eingeleitet H.C. Wainwright Buy
2017-07-12 Bestätigt Cantor Fitzgerald Overweight
2017-06-23 Herabstufung Morgan Stanley Overweight → Equal-Weight
2017-02-10 Eingeleitet Cantor Fitzgerald Overweight
2016-11-15 Bestätigt RBC Capital Mkts Outperform
2016-08-11 Eingeleitet JMP Securities Mkt Outperform
2016-02-17 Hochstufung Morgan Stanley Equal-Weight → Overweight
2015-10-23 Herabstufung Morgan Stanley Overweight → Equal-Weight
2015-08-13 Eingeleitet Morgan Stanley Overweight
Alle ansehen

Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten

pulisher
Jul 22, 2025

What drives Ocular Therapeutix Inc. stock priceOutstanding capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Ocular Therapeutix Inc. Stock Analysis and ForecastRecord-breaking gains - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Ocular Therapeutix Announces Participation in Upcoming Scientific Conferences Focused on Retina Innovation - Quiver Quantitative

Jul 22, 2025
pulisher
Jul 22, 2025

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

Ocular Therapeutix Participates in Upcoming Scientific Conferences - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

Ocular Therapeutix Unveils Breakthrough Diabetic Retinopathy Treatment Data Across 3 Major Eye Conferences - Stock Titan

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Ocular Therapeutix Inc. stockConsistently high returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Ocular Therapeutix Inc. a good long term investmentRemarkably fast returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 20, 2025

(OCUL) Trading Report - news.stocktradersdaily.com

Jul 20, 2025
pulisher
Jul 19, 2025

FMR LLC's Strategic Acquisition of Ocular Therapeutix Shares: A Financial Analysis - AInvest

Jul 19, 2025
pulisher
Jul 09, 2025

Ocular Therapeutix(OCUL) Soars 8.47% on Pipeline Progress - AInvest

Jul 09, 2025
pulisher
Jul 07, 2025

Institutional investors control 65% of Ocular Therapeutix, Inc. (NASDAQ:OCUL) and were rewarded last week after stock increased 3.7% - simplywall.st

Jul 07, 2025
pulisher
Jun 30, 2025

Ocular Therapeutix, Inc.(NasdaqGM: OCUL) dropped from Russell 3000E Index - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Ocular Therapeutix, Inc.(NasdaqGM: OCUL) dropped from Russell 3000E Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 29, 2025

Selling US$1.1m Of Ocular Therapeutix Stock Rewarded Insiders - 富途牛牛

Jun 29, 2025
pulisher
Jun 27, 2025

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company - The Manila Times

Jun 27, 2025
pulisher
Jun 26, 2025

Ocular Therapeutix Launches New Corporate Branding to Enhance Retina-Focused Mission - Nasdaq

Jun 26, 2025
pulisher
Jun 25, 2025

Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last? - Yahoo Finance

Jun 25, 2025
pulisher
Jun 24, 2025

Pre-market Movers: NKTR, INM, IBIO, IBO... - RTTNews

Jun 24, 2025
pulisher
Jun 23, 2025

OCUL SEC FilingsOcular Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 23, 2025
pulisher
Jun 19, 2025

Trend Tracker for (OCUL) - news.stocktradersdaily.com

Jun 19, 2025
pulisher
Jun 18, 2025

Ocular Therapeutix to present at Clinical Trials at the Summit 2025 - Ophthalmology Times

Jun 18, 2025
pulisher
Jun 17, 2025

Ocular Therapeutix (NASDAQ:OCUL) shareholders have earned a 33% CAGR over the last three years - Yahoo Finance

Jun 17, 2025
pulisher
Jun 16, 2025

Ocular's Make-Or-Break Moment: Axpaxli Data Looms For Wet AMD Market (Upgrade) (OCUL) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025 | OCUL Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Ocular Therapeutix, Inc. to Present Clinical Trial Results and Insights at Summit 2025 in Las Vegas - Nasdaq

Jun 16, 2025
pulisher
Jun 16, 2025

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025 - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

Breakthrough Eye Disease Treatment Data: Ocular Therapeutix Reveals Clinical Trial Results at CTS 2025 - Stock Titan

Jun 16, 2025
pulisher
Jun 11, 2025

Ocular Therapeutix Approves Key Amendments at Annual Meeting - TipRanks

Jun 11, 2025
pulisher
Jun 11, 2025

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology - insights.citeline.com

Jun 11, 2025
pulisher
Jun 10, 2025

Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) 26% Jump Shows Its Popularity With Investors - simplywall.st

Jun 10, 2025
pulisher
Jun 06, 2025

Trading (OCUL) With Integrated Risk Controls - news.stocktradersdaily.com

Jun 06, 2025
pulisher
Jun 03, 2025

Ameriprise Financial Inc. Purchases 40,700 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Two Sigma Investments LP Buys 45,518 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Nuveen Asset Management LLC Has $3.54 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

What is HC Wainwright’s Forecast for OCUL Q1 Earnings? - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Ocular gains as Wet AMD trial for lead asset reaches enrollment target - MSN

Jun 01, 2025
pulisher
May 30, 2025

Ocular Therapeutix (NASDAQ:OCUL) Given Buy Rating at HC Wainwright - Defense World

May 30, 2025
pulisher
May 30, 2025

Ocular Therapeutix (OCUL) Maintains "Buy" Rating with $15 Price Target | OCUL Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Millennium Management LLC Takes $3.82 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World

May 30, 2025
pulisher
May 30, 2025

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Holdings Lessened by Bank of America Corp DE - Defense World

May 30, 2025
pulisher
May 29, 2025

Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews - Benzinga

May 29, 2025
pulisher
May 29, 2025

Ocular Therapeutix (OCUL) Advances with Axpaxli Trial Completion - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Ocular Therapeutix (NASDAQ:OCUL) Has Debt But No Earnings; Should You Worry? - simplywall.st

May 29, 2025
pulisher
May 28, 2025

Sector Update: Health Care - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Ocular Shares Rise After Eye Disease Trial Nears Enrollment Completion - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Ocular stock gains after wet AMD trial update (OCUL:NASDAQ) - Seeking Alpha

May 28, 2025

Finanzdaten der Ocular Therapeutix Inc-Aktie (OCUL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):